{"entity":{"id":"ter-2013","kind":"drug","name":"TER-2013","aka":[],"tldr":"TER-2013 is an experimental oral small-molecule inhibitor from Terremoto Biosciences, in phase 1 trials for HR-positive HER2-negative breast cancer with PIK3CA, AKT1 or PTEN alterations, endometrial cancer and ovarian cancer and other cancers.","summary":"TER-2013 is an oral small-molecule inhibitor (AKT1-selective) from Terremoto Biosciences. An oral small molecule designed to selectively inhibit AKT1 while sparing AKT2 and AKT3, aiming to avoid the AKT2-linked high blood sugar, and the rash and diarrhoea, seen with earlier pan-AKT inhibitors. Its furthest stage is phase 1, for HR-positive HER2-negative breast cancer with PIK3CA, AKT1 or PTEN alterations, endometrial cancer, ovarian cancer and cervical cancer. ClinicalTrials.gov registers it in one study linked below. Registry: NCT07109726 phase 1/2, recruiting (start 2025-09-23). Company pipeline says it is 'currently being evaluated in a Phase 1 clinical trial'. FDA Fast Track per company release dated 3 June 2026. Whether it works in people has not been established unless a trial below reports it.","status":"phase-1","asOf":"2026-11-03","links":[{"label":"Terremoto Biosciences: terremotobio.com","url":"https://terremotobio.com/pipeline/"},{"label":"Terremoto Biosciences: terremotobio.com","url":"https://terremotobio.com/pipeline/"},{"label":"Terremoto Biosciences: terremotobio.com","url":"https://terremotobio.com/press-release/terremoto-biosciences-granted-fda-fast-track-designation-for-ter-2013-an-akt1-selective-small-molecule-inhibitor-for-breast-cancer/"},{"label":"Terremoto Biosciences: clinicaltrials.gov","url":"https://clinicaltrials.gov/api/v2/studies/NCT07109726"},{"label":"ClinicalTrials.gov: trials of TER-2013","url":"https://clinicaltrials.gov/search?intr=TER-2013"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["breast-hr-positive","endometrial","ovarian","cervical","lung-squamous-cell-carcinoma","head-and-neck"],"sections":[],"technologies":[],"targets":["akt"],"drugs":[],"companies":["terremoto-biosciences"],"institutions":[],"pathways":[],"terms":[],"trials":["nct07109726"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo gap audit, class 5 (company pipeline pages and ClinicalTrials.gov v2)","editedOn":"2026-11-03"},"code":"TER-2013","modality":"Oral small-molecule inhibitor (AKT1-selective)","mechanism":"An oral small molecule designed to selectively inhibit AKT1 while sparing AKT2 and AKT3, aiming to avoid the AKT2-linked high blood sugar, and the rash and diarrhoea, seen with earlier pan-AKT inhibitors.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/ter-2013/","neighbours":{"cancer":[{"id":"cervical","kind":"cancer","name":"Cervical cancer","route":"/cancers/cervical/"},{"id":"endometrial","kind":"cancer","name":"Endometrial cancer","route":"/cancers/endometrial/"},{"id":"head-and-neck","kind":"cancer","name":"Head and neck squamous cell carcinoma","route":"/cancers/head-and-neck/"},{"id":"breast-hr-positive","kind":"cancer","name":"HR-positive / HER2-negative breast cancer","route":"/cancers/breast-hr-positive/"},{"id":"ovarian","kind":"cancer","name":"Ovarian cancer","route":"/cancers/ovarian/"},{"id":"lung-squamous-cell-carcinoma","kind":"cancer","name":"Squamous cell carcinoma of the lung","route":"/cancers/lung-squamous-cell-carcinoma/"}],"target":[{"id":"akt","kind":"target","name":"AKT","route":"/targets/akt/"}],"company":[{"id":"terremoto-biosciences","kind":"company","name":"Terremoto Biosciences","route":"/companies/terremoto-biosciences/"}],"trial":[{"id":"nct07109726","kind":"trial","name":"A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations","route":"/trials/nct07109726/"}]}}